Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing
Reexamination Certificate
2007-04-17
2007-04-17
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
C424S185100, C424S190100, C435S005000, C435S180000, C435S181000, C435S188000
Reexamination Certificate
active
10674666
ABSTRACT:
The present invention is directed to methods of modulating viral replication in vivo comprising administering to an individual a therapeutically or prophylactically effective amount of a composition comprising arginine deiminase modified with polyethylene glycol, to methods of concurrently modulating viral replication and treating cancer, and to methods of modulating nitric oxide levels in a patient, among others.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 5372942 (1994-12-01), McGarrity et al.
patent: 5447722 (1995-09-01), Lang et al.
patent: 5468478 (1995-11-01), Saifer et al.
patent: 5474928 (1995-12-01), Takaku et al.
patent: 5804183 (1998-09-01), Filpula et al.
patent: 6183738 (2001-02-01), Clark
patent: 6737259 (2004-05-01), Clark
patent: 0 372 752 (1990-06-01), None
patent: 2-053490 (1990-02-01), None
patent: 4-121187 (1992-04-01), None
patent: WO94/05332 (1994-03-01), None
patent: WO96/34015 (1996-10-01), None
patent: WO 99/42568 (1999-08-01), None
patent: WO 01/83774 (2001-11-01), None
patent: WO 02/44360 (2002-06-01), None
Torre et al. Role of nitrix oxide in HIV-1 infection: friend or foe? Lancet Infect Dis. May 2002;(5): 273-80.
Oberg et al. Screening for new agents. Eur. J. Clin. Microbol. Infect Dis., Jul. 1990, vol. 9, No. 7, p. 466-471.
Saunders. Non-nucleoside inhibitors of HIV reverse transcriptase: screening sucesses-clinical failures. Drug Design and Discovery. 1992, vol. 8, pp. 255-263.
Yarcoan et al. Correlations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development. J. Enzyme Inhibition. 1992, vol. 6, pp. 99-111.
Wiltink et al. Antiviral drugs. Pharmaceutisch Weekblad Scientific edition. 1991, vol. 13, No. 2, pp. 58-69.
Fields et al. Fields Virology. Lippincott Williams & Wilkins, 4th Edition, 2001, vol. 1,1137.
Dev et al. Antiviral Therapy: Future Treatment of Hepatitis C: What's around the Corner. Infect. Med. 2001, vol. 21, No. 1: p. 28-36.
Izzo et al. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. Journal of Gastroenterology and Hepatology, published online Jul. 5, 2006.
Sun, et al., “Incidence and cofactors of hepatitis C virus-related heptacellular carcinoma: a prospective study of 12,008 men in Taiwan,” Am. J. Epidemiol. (2002) 157:674-682.
Herrine, “Approach to the patient with chronic haptitis C virus infection,” Ann. Intern. Med. (2002) 136:747-757.
Hoofnagle, “Course and outcome of hepatitis C,” Hepatology (2002) 36:S21-S29.
Lauer and Walker, “ Hepatitis C virus infection,” (2001) N.Engl. J. Med. (2001) 345:41-52.
Liang, et al., “Prognosis, natural history, treatment, and prevention of hepatitis C,” Ann. Intern. Med. (2001) 132:296-305.
Shiratori, et al., “Interfereon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus,” Ann. Intern. Med. (2003) 138:299-306.
Smith, et al., “Identification of novel tumor markers in hepatitis C virus-associated heptaocellular carcinoma,” Cancer Res. (2003) 63:859-864.
Yoshizawa, “Hepatocellular carcinoma associated with hepatitis C virus infection in Japan. Projection to other countries foreseeable future,” Oncology (2002) 62 (Supp. 1): 8-17.
Colombo, “Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma,” J. Hepatol. (1999) 31 (Supp 1):25-30.
El-Serag. “Hepatocellular carcinoma and hepatitis C in the United States.” Hepatclogy (2002) 36:S74-S83.
Ryder, “Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults,” Gut (2003) 52 (Supp III): iii1-iii8.
El-Serag, “Global epidemiology of hepatocellular carcinoma,” Clin. Liver Dis. (2001) 5:87-107.
DiMaio, et al., “Hepatocellular carcinoma: systemic treatments,” J. Clin. Gastroenterol. (2002) 35 (Supp. 2):S109-S114.
Curley, et al., “Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis,” Ann. Surg. (2000) 232:381-391.
Watkins and Curley, “Liver and bite ducts,” in Clinical Oncology, 2nd ed., Abeloff, et al., eds., New York, pp. 1681-1748, 2000.
Ensor, et al., “Pegylated arginine deaminase (ADI-SS PEG 20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo,” Cancer Res. (2002) 62:5443-5447.
Takaku, et al., “Chemical modification by polyethylene glycol of the antitumor enzyme arginine deaminase from Mycoplasma arginini,” Jpn. J. Cancer Res. (1983) 84:1195-1200.
Takaku, et al., “In vivo anti-tumor activity of arginine deaminase purified from Mycoplasma arginini,” Int. J. Cancer (1992) 51:244-249.
Sugimura. et al., “High sensitivity of human melanoma cell lines to the growth inhibiting activity of Mycoplasma arginini deaminase in vitro,” Melanoma Res. (1992) 2:191-196.
Rose, “Amino acid requirements of man,” Fed. Proc. (1949) 8:546-552.
Snyderman, et al., “The arginine requirement of the infant,” J. Dis. Child (1959) 97:192.
Shen, et al., “Resistance to the anti-proliferative activity of recombinant arginie deaminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase,” Cancer Lett. (2003) 191:165-170.
Falck-Ytter, et al., “Surprisingly small effect of antiviral treatment in patients with hepatitis C,” Ann Intern. Med. (2002) 136:288-292.
Fried, “Side effects of therapy of hepatitis C and their management,” Hepatology (2002) 36:S237-S244.
Fried, et al., “PEGinterferon alpha-2a plus ribavirin for chronic hepatitis C infection,” N. Engl. J. Med. (2002) 347:975-982.
Manns, et al., “PEGinterferon alpha-2b plus ribavirin compared with interferon alpha 2b plus ribavirin for initial treatment of chronic hepatitis c: a randomized trial.” Lancel (2001) 358:958-965.
Dantzler and Lawitz, “Treatment of chronic hepatitis C in nonresponders to previous therapy,” Curr. Gastroenterol. Rep. (2003) 5:78-85.
Masci, et al., “New and modified interferon alfas: preclinical and clinical data,” Curr. Oncol. Rep. (2003) 5:108-113.
Chandler, et al., “Treatment of chronic hepatitis C: a systematic review,” Hepatology (2002) 36:S135-S144.
DiBisceglie and Hoofnagle, “Optimal therapy of hepatitis C, ” Hepatology (2002) 36:S121-S127.
Lindsay, “Introduction to therapy to hepatitis C.” (2002) Hepatology (2002) 36:S114-S120.
Lopez-Guerrero and Carrasco, “Effect of nitric oxide on poliovirus infection of two human cell lines,” J. Virol. (1998) 72:2538-2540.
Wedemeyer, et al., “Polyethylene glycol-interferon: current status in hepatitis C virus therapy,” J. Gastroenterol. Hepatol. (2002) 17 (Supp 3):S344-S350.
McHutchinson, et al, “Interferon alfa-2b alone or in combination with ribavirin as intial treatment for chronic hepatitis C,” N. Eng. J. Med. (1998) 339:1485-1492.
Diamond and Lee, “Use of antiviral therapy in patients with hepatitis C,” Ann. Intern. Med. (2002) 137:1012.
Johnston and Hoth, “Present status and future prospects for HIV therapies,” Science (1993) 260:1286-1293.
Richman, “HIV therapeutics,” Science (1996) 272:1886-1888.
Christie and Chapman, “Combination therapy for chronic hepatitis C: interferon and ribavirin,” Hosp. Med. (1999) 60:357.
Rouse, et al., “Dependence of adenovirus replication on arginina and inhibition of plaque formation by pleuropneumonia-like organisms,” Virology (1963) 20:357-365.
Tankersley, “Amino acid requirements of herpes simplex virus in human cells, ” J. Bacteriol. (1964) 87:608-613.
Goldblum, et al., “Effect of withdrawl of arginine and other amino acids on the synthesis of tumor and viral antigens of SV40 virus,” J
Campell Bruce R.
Le Emily M.
Phoenix Pharmacologics, Inc.
Woodcock & Washburn LLP
LandOfFree
Methods for inhibiting viral replication in vivo does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting viral replication in vivo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting viral replication in vivo will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3764743